Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin group therapy for depression in low-income patients
NCT06372197Completed
- Start
- Aug 2024
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of psilocybin in major depressive disorder (MDD). Primary endpoints: Recruitment Feasibility at 18 months, Retention Feasibility at 18 months and 2 more. Started Aug 2024; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06372197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06372197.